A Phase III, randomised, double blind, placebo-controlled, parallel-group multicentre efficacy and safety study of Gantenerumab in patients with mild Alzheimer’s disease.
DEMENTIA TRIALS AUSTRALIA
A Phase III, randomised, double blind, placebo-controlled, parallel-group multicentre efficacy and safety study of Gantenerumab in patients with mild Alzheimer’s disease.